Session » (2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II
- 10:30AM-12:30PM
-
Abstract Number: 2120
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
- 10:30AM-12:30PM
-
Abstract Number: 2109
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
- 10:30AM-12:30PM
-
Abstract Number: 2111
Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
- 10:30AM-12:30PM
-
Abstract Number: 2117
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
- 10:30AM-12:30PM
-
Abstract Number: 2114
Development of a Fracture Prediction Model for Patients Aging with HIV
- 10:30AM-12:30PM
-
Abstract Number: 2110
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
- 10:30AM-12:30PM
-
Abstract Number: 2107
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
- 10:30AM-12:30PM
-
Abstract Number: 2119
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
- 10:30AM-12:30PM
-
Abstract Number: 2115
METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
- 10:30AM-12:30PM
-
Abstract Number: 2113
Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
- 10:30AM-12:30PM
-
Abstract Number: 2108
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
- 10:30AM-12:30PM
-
Abstract Number: 2106
Prevalence and Characteristics of Morphometric Vertebral Fractures in the Spanish Population: Data from the OsteoSER Study
- 10:30AM-12:30PM
-
Abstract Number: 2121
Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
- 10:30AM-12:30PM
-
Abstract Number: 2118
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
- 10:30AM-12:30PM
-
Abstract Number: 2116
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
- 10:30AM-12:30PM
-
Abstract Number: 2122
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
- 10:30AM-12:30PM
-
Abstract Number: 2123
Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia